Results 71 to 80 of about 34,473 (219)
Journal of International Medical Research, 2020 Central nervous system aspergillosis (CNS-A) is a rare and fatal fungal infection. Voriconazole is the recommended treatment for CNS-A. The therapeutic effect of voriconazole is good, but its use is limited due to adverse reactions.
Zhaohao Zeng +9 more
doaj +1 more source
Platelet‐Rich Fibrins as Local Drug‐Delivery Carriers
Journal of Periodontal Research, EarlyView.Autologous platelet concentrates (APCs), particularly platelet‐rich fibrin (PRF), act as biologically active fibrin scaffolds, capable of entrapping and gradually releasing therapeutic agents in oral and periodontal therapy. The incorporation of bioactive compounds, such as antibiotics, antifungals, vitamins, antidiabetic drugs, and exosomes, enhances ...
Karim M. Fawzy El‐Sayed +1 more
wiley +1 more source
Voriconazole Induced Bullous Phototoxicity [PDF]
, 2019 Introduction: Voriconazole, commonly used for invasive aspergillosis treatment, can cause cutaneous adverse effects including photosensitivity. We outline a case of bullous phototoxicity secondary to voriconazole, a condition seldom reported. Case Report:
Pritchett, Ellen N +2 more
core +1 more source
Voriconazole plasma monitoring
, 2008 Aims: Very little information is available regarding the use of voriconazole drug monitoring in children with invasive fungal infections. The purpose of this study was to report the cases of five paediatric patients treated with voriconazole, in which ...
Denning, D. W.; id_orcid +3 more
core +1 more source
Invasive sphenoidal aspergillosis: successful treatment with sphenoidotomy and voriconazole [PDF]
, 2007 Treatment of invasive sphenoidal aspergillosis is surgical, followed by antifungal therapy, mostly amphotericin B. To optimize the adjuvant antifungal treatment, which is often limited by severe side effects, the new triazole antifungal agent ...
Baumann, Ariane +3 more
core +1 more source
Impact of Letermovir on Voriconazole Concentrations in Lung Transplant Patients
Transplant Infectious Disease, EarlyView.Concomitant letermovir was associated with lower voriconazole exposure and reduced attainment of commonly used efficacy thresholds in lung transplant recipients. Routine therapeutic drug monitoring after letermovir initiation is recommended, and empiric voriconazole dose escalation may be needed to avoid subtherapeutic exposure. ABSTRACT Background The
Leah Georgiades +6 more
wiley +1 more source
Frontiers in PharmacologyVoriconazole, a broad-spectrum antifungal agent, is considered the first-line treatment for invasive aspergillosis. In this article, we report three cases of patients who experienced visual disturbances and hallucinations following voriconazole therapy ...
Ya Liu +4 more
doaj +1 more source
Overview of voriconazole [PDF]
, 2005 Voriconazole（VRCZ）は，日本では2005年4月に承認された新しいトリアゾール系抗真菌薬である。バイオアベイラビリティの高さと広範な抗真菌スペクトルが特徴であり，従来の抗真菌薬が効きにくいCandida glabrata，Candida krusei，ならびにアスペルギルス属，フサリウム属，スケドスポリウム属にも抗真菌作用を発揮する。注射薬と経口薬の両剤形があるため，静注療法から経口療法への切り替えも可能である。深在性真菌症の感染部位となる肺，肝，腎，脳，眼などへの組織移行性に優れている ...
河野, 茂
core
Transplant Infectious Disease, EarlyView.In this 10‐year retrospective cohort study of heart transplant recipients in subtropical Australia, we characterize the incidence and microbiological profile of invasive fungal infections, highlighting the underappreciated burden of late‐onset and non‐Aspergillus mold infections and the potential underdiagnosis of polymicrobial disease.
Angus Lane +7 more
wiley +1 more source
Determination of a suitable voriconazole pharmacokinetic model for personalised dosing
, 2016 Model based personalised dosing (MBPD) is a sophisticated form of individualised therapy, where a population pharmacokinetic (PK) or pharmacodynamic model is utilised to estimate the dose required to reach a target exposure or effect. The choice of which
Playford, EG +3 more
core +1 more source